Advanced Medical Solutions has highlighted new data from a pair of clinical studies that showcase the benefits of its silver alginate woundcare products.

Data from the studies has been published in the International Wound Journal and the Journal of Woundcare, showing the antimicrobial efficacy of one of its commercialised silver alginate dressings in killing 160 chronic and burn wound microorganisms.

This includes 29 strains of the superbug MRSA, which is recognised as one of the most difficult infections to treat.

Chris Meredith, chief executive officer of Advanced Medical Solutions, said positive clinical data of this kind will help to drive further commercial success of its products.

"Our quality silver alginate products ... have helped our partners successfully capture 20 percent of the $230 million (145.1 million pounds) global antimicrobial fibre market in the last five years," he said.

Last month, the firm announced that it remains on track to meet its financial targets for 2011 after a enjoying a strong start to the current business year.